Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 1751 to 1760 of 2610 total matches.
Homeopathic Products
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Some patients may ask physicians about the effectiveness and safety of homeopathic drugs, which are marketed through health food stores, pharmacies, direct mail and person-to-person sales, and promoted for use in a wide range of disorders.
Prozac Weekly
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001 (Issue 1101)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine (Prozac).
Is Accutane really dangerous?
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Isotretinoin (Accutane - Roche), an effective oral drug for treatment of acne, will soon be available generically. Concerns about its adverse effects, particularly psychiatric symptoms in adolescents, have been widely reported in the media.
In Brief: Vitamin B12 Nasal Spray
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005 (Issue 1214)
Letter
®
On Drugs and Therapeutics
Volume 47 (Issue 1214)
August 1, 2005
www.medicalletter.org ...
A nasal spray formulation of cyanocobalamin (Nascobal – Questcor) has been approved by the FDA for maintenance treatment of vitamin B12 deficiency. Nascobal is already available as an intranasal gel. Vitamin B12 deficiency, diagnosed by elevated serum concentrations of methylmalonic acid with or without elevated serum homocysteine and low serum B12 concentrations (<200 pg/mL), is common in older patients.1Since intestinal absorption of B12 may be impaired, the usual maintenance treatment of deficiency is intramuscular injection of the vitamin in doses of 1 mg every 4 weeks (after more...
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1287)
June 2, 2008
www.medicalletter.org ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Denosumab (Prolia) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2010 (Issue 1349)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issue 1349)
October 18, 2010 ...
The FDA has approved use of denosumab (Prolia –
Amgen) for treatment of osteoporosis in postmenopausal
women at high risk for fracture.
Miconazole (Oravig) for Oropharyngeal Candidiasis
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010 (Issue 1352)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issue 1352)
November 29, 2010 ...
The FDA has approved a buccal tablet formulation of
miconazole (Oravig – Strativa) for local treatment of
oropharyngeal candidiasis in adults. Miconazole has
been available for many years in topical formulations
for treatment of superficial fungal infections and vulvovaginal
candidiasis.
Botulinum Toxin for Chronic Migraine
The Medical Letter on Drugs and Therapeutics • Jan 24, 2011 (Issue 1356)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issues 1356)
January 24, 2011 ...
The FDA has approved injection of onabotulinumtoxinA
(Botox – Allergan) for prevention of
headaches in adult patients with chronic migraine (≥15
headache days/month for ≥3 months). It is the first
drug approved for treatment of this indication. Botox is
also FDA-approved for treatment of upper limb spasticity,
axillary hyperhidrosis, cervical dystonia, blepharospasm
and strabismus, and for cosmetic
reduction of wrinkles.
Capsaicin Patch (Qutenza) for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • May 30, 2011 (Issue 1365)
Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1365)
May 30, 2011
www.medicalletter.org ...
The FDA has approved a topical 8% patch formulation
of capsaicin (Qutenza – NeurogesX), available only by
prescription, for local treatment of postherpetic neuralgia.
Postherpetic neuralgia occurs after herpes zoster
in about one third of patients ≥60 years old and can
persist for months or even years.
Azilsartan Medoxomil (Edarbi) - The Eighth ARB
The Medical Letter on Drugs and Therapeutics • May 16, 2011 (Issue 1364)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1364)
May 16, 2011 ...
The angiotensin receptor blocker (ARB) azilsartan
medoxomil (Edarbi – Takeda) was recently approved
by the FDA for oral treatment of hypertension, either
alone or combined with other drugs. It is the eighth
ARB approved for this indication.